Koninklijke Philips (NYSE:PHG) Upgraded at Sanford C. Bernstein

Sanford C. Bernstein upgraded shares of Koninklijke Philips (NYSE:PHG) from a hold rating to a strong-buy rating in a research report released on Tuesday,Zacks.com reports.

Several other analysts have also weighed in on PHG. StockNews.com raised Koninklijke Philips from a “hold” rating to a “buy” rating in a report on Saturday, March 8th. BNP Paribas raised Koninklijke Philips from a “neutral” rating to an “outperform” rating in a report on Tuesday, February 25th. Finally, UBS Group raised Koninklijke Philips from a “neutral” rating to a “buy” rating in a research note on Thursday, February 20th. Two analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Koninklijke Philips has an average rating of “Moderate Buy”.

Koninklijke Philips Stock Down 3.4 %

Koninklijke Philips stock opened at $25.88 on Tuesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.74 and a current ratio of 1.23. The firm has a market capitalization of $24.32 billion, a price-to-earnings ratio of -30.80, a price-to-earnings-growth ratio of 0.82 and a beta of 0.78. Koninklijke Philips has a fifty-two week low of $19.10 and a fifty-two week high of $32.91. The stock’s fifty day moving average is $26.74 and its two-hundred day moving average is $27.77.

Koninklijke Philips (NYSE:PHG) last posted its earnings results on Wednesday, February 19th. The technology company reported $0.54 earnings per share for the quarter, missing the consensus estimate of $0.55 by ($0.01). The firm had revenue of $5.38 billion during the quarter, compared to analyst estimates of $5.10 billion. Koninklijke Philips had a negative net margin of 3.88% and a positive return on equity of 10.85%. Analysts predict that Koninklijke Philips will post 1.63 EPS for the current fiscal year.

Koninklijke Philips Cuts Dividend

The firm also recently declared an annual dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 13th will be issued a $0.886 dividend. The ex-dividend date of this dividend is Tuesday, May 13th. This represents a yield of 2.9%. Koninklijke Philips’s dividend payout ratio (DPR) is presently -89.29%.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Colonial Trust Co SC lifted its stake in shares of Koninklijke Philips by 724.0% during the 4th quarter. Colonial Trust Co SC now owns 1,409 shares of the technology company’s stock worth $36,000 after purchasing an additional 1,238 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in shares of Koninklijke Philips during the 3rd quarter worth $54,000. Farther Finance Advisors LLC lifted its stake in shares of Koninklijke Philips by 37.1% during the 4th quarter. Farther Finance Advisors LLC now owns 2,150 shares of the technology company’s stock worth $54,000 after purchasing an additional 582 shares during the period. Whipplewood Advisors LLC purchased a new position in shares of Koninklijke Philips during the 4th quarter worth $55,000. Finally, Millstone Evans Group LLC purchased a new position in shares of Koninklijke Philips during the 4th quarter worth $60,000. Hedge funds and other institutional investors own 13.67% of the company’s stock.

Koninklijke Philips Company Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.